Literature DB >> 7980587

Purification and characterization of brain clusterin.

T Oda1, G M Pasinetti, H H Osterburg, C Anderson, S A Johnson, C E Finch.   

Abstract

Clusterin, a 70-80 kDa sulfated glycoprotein found in numerous tissues, is also known as complement lysis inhibitor (CLI), apolipoprotein J, SP-40,40, TRPM-2, and SGP-2. In Alzheimer disease (AD), clusterin mRNA is increased, whereas clusterin protein is found in deposits of beta-amyloid (A beta). These studies characterized clusterin protein from human brain. In extracts from cortex and hippocampus, clusterin was about 40% higher in AD than in controls. Purified clusterin from human brain was slightly smaller than serum clusterin. Brain and serum clusterin were indistinguishable in the inhibition of complement-mediated hemolysis. Both serum and brain clusterin were indistinguishable in inhibiting the aggregation of A beta and promoting oxidative stress in rat pheochromocytoma PC12 cells (MTT assay). The inhibition of A beta aggregation and enhancement of A beta toxicity by clusterin suggest new mechanisms in AD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980587     DOI: 10.1006/bbrc.1994.2580

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease.

Authors:  W G Wood; F Schroeder; N A Avdulov; S V Chochina; U Igbavboa
Journal:  Lipids       Date:  1999-03       Impact factor: 1.880

Review 2.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 3.  Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Authors:  Kyle C Wilcox; Pascale N Lacor; Jason Pitt; William L Klein
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

Review 4.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

5.  Genetic variability in CLU and its association with Alzheimer's disease.

Authors:  Rita J Guerreiro; John Beck; J Raphael Gibbs; Isabel Santana; Martin N Rossor; Jonathan M Schott; Michael A Nalls; Helena Ribeiro; Beatriz Santiago; Nick C Fox; Catarina Oliveira; John Collinge; Simon Mead; Andrew Singleton; John Hardy
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

6.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 8.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

9.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

10.  Supramolecular nanofibrils inhibit cancer progression in vitro and in vivo.

Authors:  Yi Kuang; Xuewen Du; Jie Zhou; Bing Xu
Journal:  Adv Healthc Mater       Date:  2014-02-20       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.